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Abstract
Background: There are currently no accurate serum markers for detecting early risk of colorectal cancer (CRC). We
therefore developed a non-targeted metabolomics technology to analyse the serum of pre-treatment CRC patients
in order to discover putative metabolic markers associated with CRC. Using tandem-mass spectrometry (MS/MS)
high throughput MS technology we evaluated the utility of selected markers and this technology for discriminating
between CRC and healthy subjects.
Methods: Biomarker discovery was performed using Fourier transform ion cyclotron resonance mass spectrometry
(FTICR-MS). Comprehensive metabolic profiles of CRC patients and controls from three independent populations
from different continents (USA and Japan; total n = 222) were obtained and the best inter-study biomarkers
determined. The structural characterization of these and related markers was performed using liquid
chromatography (LC) MS/MS and nuclear magnetic resonance technologies. Clinical utility evaluations were
performed using a targeted high-throughput triple-quadrupole multiple reaction monitoring (TQ-MRM) method for
three biomarkers in two further independent populations from the USA and Japan (total n = 220).
Results: Comprehensive metabolomic analyses revealed significantly reduced levels of 28-36 carbon-containing
hydroxylated polyunsaturated ultra long-chain fatty-acids in all three independent cohorts of CRC patient samples
relative to controls. Structure elucidation studies on the C28 molecules revealed two families harbouring specifically
two or three hydroxyl substitutions and varying degrees of unsaturation. The TQ-MRM method successfully
validated the FTICR-MS results in two further independent studies. In total, biomarkers in five independent
populations across two continental regions were evaluated (three populations by FTICR-MS and two by TQ-MRM).
The resultant receiver-operator characteristic curve AUCs ranged from 0.85 to 0.98 (average = 0.91 ± 0.04).
Conclusions: A novel comprehensive metabolomics technology was used to identify a systemic metabolic
dysregulation comprising previously unknown hydroxylated polyunsaturated ultra-long chain fatty acid metabolites
in CRC patients. These metabolites are easily measurable in serum and a decrease in their concentration appears to
be highly sensitive and specific for the presence of CRC, regardless of ethnic or geographic background. The
measurement of these metabolites may represent an additional tool for the early detection and screening of CRC.
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Colorectal cancer (CRC) mortality remains one of the
highest among all cancers, second to only lung cancer
(Canadian Cancer Statistics, 2008). Despite the known
benefits of early detection, screening programmes based
on colonoscopy and fecal occult blood testing have been
plagued with challenges such as public acceptance, cost,
limited resources, accuracy and standardization. There is
consensus in the field that the use of colonoscopy alone
for CRC screening is not practical [1], and that a mini-
mally-invasive serum-based test capable of accurately
identifying subjects who are high risk for the develop-
ment of CRC would result in a higher screening compli-
ance than current approaches and better utilization of
existing endoscopy resources [1-3]. Although there have
been multiple reports of altered transcript levels [4-11],
aberrantly methylated gene products [12-14] and proteo-
mic patterns [15-18] associated with biological samples
from CRC patients, few if any have advanced into clini-
cally useful tests. This may be due to a number of rea-
sons including technical hurdles in assay design,
challenges obtaining reproducible results, costs and
lengthy regulatory processes. Furthermore, most of the
tests currently used or in development are based upon
the detection of tumour-specific markers and have poor
sensitivity for identifying subjects who are either very
early stage, or are predisposed to risk but show no clini-
cal presentation of disease.
Although causal genetic alterations for CRC have been
well characterized, the number of cases due to adenoma-
tous (APC) and hereditary nonpolyposs colorectal cancer
are less than 5% of the total, with approximately 15%
claimed to be attributable to inheritable family risk likely
due to complex patterns of low penetrance mutations
which have yet to be delineated [19]. The fact remains
that approximately 80% of CRC cases are thought to
arise sporadically, with diet and lifestyle as key risk fac-
tors [20,21]. In addition, an individual’s microbiome is
intricately linked to their gastrointestinal physiological
status and may itself be involved as a risk factor [22].
Given that metabolism is heavily influenced by both diet
and lifestyle and that the microbiome contributes its own
metabolic processes, it is surprising that there has been
little effort aimed identifying metabolic markers as risk
indicators of CRC. This may, in part, have been due to
t h el a c ko fp l a t f o r mt e c h n o l o g i e sa n di n f o r m a t i c s
approaches capable of comprehensively characterizing
metabolites in a similar way that DNA microarrays or
surface-enhanced laser desorption ionization can charac-
terize transcripts or proteins, respectively.
Recently, however, there have been rapid advances
made in mass spectrometric-based systems which can
identify large numbers of metabolic components within
samples in a parallel manner [23-25]. Fourier transform
ion cyclotron resonance mass spectrometry (FTICR-MS)
is based upon the principle that charged particles exhibit
cyclotron motion in a magnetic field, where the spin fre-
quency is proportional the mass [26]. FTICR-MS is
known for its high resolving power and capability of
detecting ions with mass accuracy below 1 part per mil-
lion (ppm). Liquid sample extracts can be directly
infused using electrospray ionization (ESI) and atmo-
spheric pressure chemical ionization (APCI) without
chromatographic separation [23], where ions with differ-
ing mass to charge (m/z) ratios can be simultaneously
resolved using a Fourier transformation. Using infor-
matics approaches, spectral files from multiple samples
can be accurately aligned and peak intensities across the
samples compared [23]. High resolution also enables the
prediction of elemental composition of all ions detected
in a sample, providing a solid foundation for metabolite
classification and identification, as well as the ability to
construct de novo metabolic networks [23,27]. The com-
bination of liquid extraction, flow injection, high resolu-
tion and informatics affords a unique opportunity to
broadly characterize the biochemical composition of
samples, with no ap r i o r iknowledge about the sample
itself, to a degree which was not previously possible.
This ‘non-targeted’ approach has the advantage of
detecting novel compounds and is therefore ideally sui-
ted for biomarker-driven discovery applications. Using a
MS-based discovery platform for metabolic biomarker
identification also has the added advantage of straight-
forward translation into a quantitative method based
upon triple-quadruple multiple-reaction-monitoring
(TQ-MRM), similar to the clinical methods used to
screen for inborn errors of metabolism [28].
Here we report on the application of this technology
for characterizing the serum metabolomes of treatment-
naive CRC patients and healthy asymptomatic subjects.
A specific metabolic perturbation was discovered in the
serum of CRC patients compared to controls in three
independent and unrelated sets of samples (total n of
222). We further verify the perturbation using a tandem
MS (MS/MS) approach in two additional independent
case-control populations totalling 220 subjects. Implica-
tions of the findings for CRC screening are discussed.
Methods
Patient sample selection
Clinical samples used for the first discovery project were
obtained from Genomics Collaborative, Inc (GCI, MA,
USA), while samples for the second discovery project
and one validation project were obtained from Seracare
Lifesciences (MA, USA). These companies specialize in
the collection and storage of serum and tissue samples
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lected, processed and stored in a consistent manner by
teams of physicians as part of a global initiative using
standardized protocols and operating procedures. Col-
lection protocols for GCI and Seracare Lifesciences were
approved by the Western Institutional Review Board
and all samples were properly consented. The inclusion
criterion for patient sample selection from the GCI and
Seracare biobanks for both the discovery and validation
cohorts was that the serum be taken prior to any form
of treatment, including surgery, chemo or radiation
therapies. All samples were accompanied by detailed
pathology reports which were independently verified by
certified pathologists at GCI and Seracare. The GCI dis-
covery sample set included serum samples from 40 pre-
treatment CRC patients and matched 50 controls; the
Seracare discovery set included samples from 26 pre-
treatment CRC and matched 25 controls, and the valida-
tion Seracare set included 70 pretreatment CRC and
matched 70 controls. The discovery samples provided
by Osaka Medical University (Osaka, Japan) included 46
pre-surgery CRC patients matched 35 controls which
were prospectively collected according to the standard
collection protocol of the institution and were properly
consented. Study protocols were performed according to
the ethical guidelines set by the committee of the three
ministries of the Japanese Government. The samples for
the Chiba, Japan, validation population, which included
40 pre-surgery CRC patients and 40 matched controls,
were also prospectively consented and collected under
an ethics reviewed protocol approved by the Institu-
tional Review Board of Graduate School of Medicine,
Chiba University. A summary of the populations includ-
ing disease staging is shown in Table 1. All samples
were processed and analysed in a randomized manner
and the results unblinded following analysis.
Sample extraction
Serum samples were stored at -80°C until thawed for
analysis and were only thawed once. All extractions
were performed on ice. Serum samples were prepared
for FTICR-MS analysis by first sequentially extracting
equal volumes of serum with 1% ammonium hydroxide
and ethyl acetate (EtOAc) three times. Samples were
centrifuged between extractions at 4°C for 10 min at
3500 rpm and the organic layer removed and transferred
to a new tube (extract A). A 1:5 ratio of EtOAc (extract
A) to butanol (BuOH) was then evaporated under nitro-
gen to the original BuOH starting volume (extract B).
A l le x t r a c t sw e r es t o r e da t- 8 0 ° Cu n t i lF T I C R - M S
analysis.
FTICR-MS analysis
For analysis under negative ESI conditions, sample
extract B was diluted 10-fold in methanol:0.1% (v/v)
ammonium hydroxide (50:50, v/v) prior to direct infu-
sion. For APCI, extract A was directly injected without
diluting. All analyses were performed on a Bruker Dal-
tonics APEX III FTICR-MS equipped with a 7.0 T
actively shielded superconducting magnet (Bruker Dal-
tonics, MA, USA). Samples were directly injected using
ESI and APCI at a flow rate of 600 μL per hour. Ion
transfer/detection parameters were optimized using a
standard mix of serine, tetra-alanine, reserpine, Hewlett-
Packard tuning mix and the adrenocorticotrophic hor-
mone fragment 4-10. In addition, the instrument condi-
tions were tuned to optimize ion intensity and broad-
band accumulation over the mass range of 100-1000
atomic mass units (amu) according to the instrument
manufacturer’s recommendations. A mixture of the
above mentioned standards was used to internally cali-
brate each sample spectrum for mass accuracy over the
acquisition range of 100-1000 amu. FTICR data were
Table 1 Summary of case-control populations used in this study
FTICR-MS discovery MRM validation
Genomics Collaborative Seracare 1 Osaka Chiba Seracare 2
CRC Control CRC Control CRC Control CRC Control CRC Control
Total 40 50 26 25 46 35 40 40 70 70
Male N 19 24 17 16 27 - 19 24 44 41
Male age 59 (30-78) 56 (30-78) 62 (46-80) 51 (35-70) 63 (28-90) - 68 (45-91) 48 (36-69) 67 (39-87) 63 (32-82)
Male BMI 20.9 ± 3.8 25.0 ± 0.9 24.3 ± 5.7 25.6 ± 4.6 NA - NA NA 28.0 ± 4.8 26. ± 4.2
Female N 21 26 9 9 19 - 21 16 26 29
Female age 54 (40-82) 55 (40-79) 78 (59-86) 55 (26-95) 65 (31-77) - 70 (51-84) 49 (39-59) 73 (35-90) 56 (26-86)
Female BMI 19.9 ± 4.6 24.8 ± 2.2 23 ± 3.2 29 ± 8.0 NA - NA NA 25.5 ± 4.4 24.0 ± 4.5
Stage 0/I 8-5 - 1 0 - 9 - 1 3 -
Stage II 16 - 8 - 14 - 18 - 21 -
Stage III 15 - 8 - 12 - 11 - 25 -
Stage IV 1 -2-8 - 2-7-
Unknown 0 -3-2 - 0-4-
BMI = body mass index; CRC = colorectal cancer; FTICT-MS = Fourier transform ion cyclotron resonance mass spectroscopy; MRM = multiple reaction monitoring.
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mass axis values were calibrated such that each internal
standard mass peak had a mass error of < 1 part ppm
compared with its theoretical mass. Using XMASS soft-
ware from Bruker Daltonics Inc (CA, USA), data file
sizes of one megaword were acquired and zero-filled to
two megawords. A SINm data transformation was per-
formed prior to Fourier transform and magnitude calcu-
lations. The mass spectra from each analysis were
integrated, creating a peak list that contained the accu-
rate mass and absolute intensity of each peak. Com-
pounds in the range of 100-1000 mz were analysed. In
order to compare and summarize the data, all detected
mass peaks were converted to their corresponding neu-
tral masses, assuming hydrogen adduct formation. A
self-generated two-dimensional (mass versus sample
intensity) array was then created using DISCOVA-
metrics™ software (Phenomenome Discoveries Inc, Sas-
katoon, Canada). The data from multiple files were
integrated and this combined file was then processed in
order to determine all of the unique masses. The aver-
age of each unique mass was determined, representing
the y-axis. A column was created for each file that was
originally selected to be analysed, representing the x-
axis. The intensity for each mass found in each of the
files selected was then filled into its representative x,y
coordinate. Coordinates that did not contain an inten-
sity value were left blank. Each of the spectra was then
peak-picked in order to obtain the mass and intensity of
all metabolites detected. The data from all modes were
then merged to create one data file per sample. The
data from all 90 discovery serum samples were then
merged and aligned to create a two-dimensional meta-
bolite array in which each sample is represented by a
column, each unique metabolite is represented by a sin-
gle row and each cell in the array corresponds to a
metabolite intensity for a given sample. The array tables
were then used for statistical analysis described in ‘sta-
tistical analyses’ (see Additional File 1).
Full-scan quadruple time-of-flight (Q-TOF) and high
performance liquid chromatography (HPLC)-coupled MS/
MS spectrometry
Ethyl acetate extracts from five CRC and five normal
samples were evaporated under nitrogen gas and recon-
stituted in 70 μL of isopropanol:methanol:formic acid
(10:90:0.1). Ten microlitres of the reconstituted sample
was subjected to HPLC (HP 1100 with Hypersil ODS 5
μm, 125 × 4 mm column; Agilent Technologies, CA,
USA) for full scan and 30 μL for MS/MS at a flow rate
of 1 mL/min. Eluate from the HPLC was analysed using
an ABI QSTAR® XL mass spectrometer fitted with an
APCI source in negative mode. The scan type in full
scan mode was TOF with an accumulation time of
1.0000 s, mass range between 50 and 1500 Da and dura-
tion time of 55 min. Source parameters were as follows:
ion source gas (GS) 1 80; ion GS2 10; curtain gas (CUR)
30; nebulizer current (NC) -3.0; temperature 400°C;
declustering potential (DP) -60; focusing potential (FP)
-265; DP2 -15. In MS/MS mode, scan type was product
ion, accumulation time was 1.0000 s, scan range
between 50 and 650 Da and duration time 55 min. All
source parameters are the same as above, with collision
energy (CE) of -35 V and collision gas (CID, nitrogen)
of 5 psi. For MS3 work, the excitation energy was set at
180 V.
Preliminary isolation of CRC biomarkers and NMR analysis
For the thin layer chromatographic methods, all chemi-
cals and media were purchased from Sigma-Aldrich
Canada Ltd (ON, Canada). All solvents were HPLC
grade. Analytical thin layer chromatography (TLC) was
carried out on pre-coated silica gel TLC aluminum
sheets (EM Science, NJ, USA; Kieselgel 60 F254,5×2
cm × 0.2 mm). Compounds were visualized under ultra-
violet light (254/366 nm) or placed in an iodine vapour
tank and by dipping the plates in a 5% aqueous (w/v)
phosphomolybdic acid solution containing 1% (w/v)
ceric sulphate and 4% (v/v) H2SO4, followed by heating.
NMR spectra were recorded on Bruker Avance spectro-
meters; for
1H (500 MHz), δ values were referenced to
CDCl3 (CHCl3 at 7.24 ppm) and for
13CN M R( 1 2 5 . 8
MHz) referenced to CDCl3 (77.23 ppm).
Ethyl acetate extracts of commercial serum (180 mL
serum, 500 mg extract) was subjected to reverse phase
flash column chromatography (FCC) with a step gradi-
ent elution; acetonitrile - water 25:75 to 100% acetoni-
trile. The fractions collected were analysed by LC/MS
and MS/MS. The fractions containing the CRC biomar-
kers were pooled (12.5 mg). This procedure was
repeated several times to obtain about 60 mg of CRC
biomarker rich fraction. This combined sample was then
subjected to FCC with a step gradient elution; hexane-
chloroform-methanol and the fractions collected sub-
jected to LC/MS and MS/MS analysis. The biomarker
rich fraction labelled sample A (5.4 mg, about 65%) was
analysed by NMR. Sample A (3 mg) was then treated
with excess ethereal diazomethane and kept overnight at
room temperature. After the removal of solvent, the
sample was analyzed by NMR.
TQ-MRM methodology
Serum samples were extracted as described for non-tar-
geted FTICR-MS analysis, with the addition of 10 ug/
mL [
13C1]cholic acid to the serum prior to extraction
(resulting in a final ethyl acetate concentration of [
13C1]
cholic acid of 36 nM. The ethyl acetate organic fraction
was used for the analysis of each sample. A series of
Ritchie et al. BMC Medicine 2010, 8:13
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13C1]cholic acid dilutions in ethyl acetate from Randox
serum extracts was used to generate a standard curve
ranging between 0.00022 μg/mL and 0.222 μg/mL. 100
μL of sample were injected by flow-injection analysis
into the 4000QTRAP™ equipped with a TurboV™ source
with an APCI probe. The carrier solvent was 90%
methanol:10% ethyl acetate, with a flow rate of 360 μL/
min into the APCI source. The source gas parameters
w e r ea sf o l l o w s :C U R :1 0 . 0 ,C A D :6 ,N C :- 3 . 0 ,T E M :
4 0 0 ,G S 1 :1 5 ,i n t e r f a c eh e a t e ro n .‘Compound’ settings
were as follows: entrance potential (EP): -10, and colli-
sion cell exit potential (CXP): -20.0. The method is
based on the MRM of one parent ion transition for each
of the C28 molecules (445.3-383.4 Da, 447.4-385.4 Da,
and 449.4-405.4 Da) and a single transition for the inter-
nal standard (408.3-343.4 Da). Each of the transitions
was monitored for 250 ms for a total cycle time of 2.3 s.
The total acquisition time per sample was approximately
1 min. All accepted analyses showed R
2 correlation coef-
ficients for the linear regression equation of >0.98.
[
13C1]cholic acid equivalents for each of the three C28
molecules were calculated by determining the percent
recovery of [
13C1]cholic acid in each sample by dividing
the extrapolated concentration by 0.0148 ug/ml (36 nM,
the theoretical amount present in the ethyl acetate
extract of each sample). Metabolite concentrations
represented as [
13C1]cholic acid equivalents were then
extrapolated, normalized by dividing by the percent
recovery and multiplied by appropriate extraction dilu-
tion factors to yield a final serum concentration.
Statistical analysis
FTICR-MS accurate mass array alignments were per-
formed using DISCOVAmetrics™ version 3.0 (Phenomen-
ome Discoveries Inc, Saskatoon, Canada). Statistical
analysis and graphs of FTICR-MS data was carried out
using Microsoft Office Excel 2007 and distribution analy-
sis of TQ-MRM data and was analysed using JMP version
8.0.1. Meta Analysis (Fisher’s inverse chi-square method)
was carried out using SAS 9.2 and R 2.9.0. Two-tailed
unpaired Student’s t-tests were used for determination of
significance between CRC and controls. P-values of less
than 0.05 were considered significant. Receiver operating
curve (ROC) curves were generated using the continuous
data mode of JROCFIT http://www.jrocfit.org.
Results
FTICR metabolomic profiling
The experimental workflow for the studies described in
this paper is summarized in Figure 1. Non-targeted meta-
bolomic profiles of sera from three independent popula-
tions of treatment-naive CRC patients and geographically
and ethnically matched healthy controls (summarized in
Table 1) were generated over a 24-month period (that is,
each study was separated by approximately 12 months).
The first study comprised 40 CRC patients and 50 con-
trol subjects acquired from Genomics Collaborative, Inc
(GCI); the second study comprised 26 CRC subjects and
25 controls acquired from Seracare Lifesciences Inc; and
the third study included 46 CRC and 35 controls pro-
spectively collected in Osaka, Japan. In all cases, serum
metabolites were captured through a liquid extraction
process (see Methods), followed by direct infusion of the
extracts using negative electrospray ionization (nESI) and
negative atmospheric pressure chemical ionization
(nAPCI) on an FTICR mass spectrometer. The resulting
spectral data of all the subjects for each study was aligned
within 1 ppm mass accuracy, background peaks were
subtracted, and a two-dimensional array table comprising
the intensities each of the sample-specific spectral peaks
was created using custom informatics software (see
Methods). Metabolic differences between CRC patient
and control profiles for the three independent studies
were visualized by plotting the control mean-normalized
log ratio peak intensities across the detected mass range
as shown in Figures 2A to 2C. In each independent
study, a region of spectra between approximately 440 and
600 Da showed peaks consistently reduced in intensity in
CRC patients relative to controls (green, yellow, orange
and red points in Figure 2). On average, this cluster of
masses showed between 50% and 75% reduction in CRC
patient serum compared to the respective controls, with
p-values of 1 × 10
-5 or lower in each study.
The overlap between each of the discovery studies was
further investigated by ranking the top 50 masses based
upon P-value from each study and comparing them with
masses showing a significant difference (P < 0.05 between
CRC and controls) in the other studies as shown in Table
2. For example, 46 of the top 50 metabolites (92%) with
the lowest p-values in the GCI discovery set were also sig-
nificant (P < 0.05) in the Seracare 1 dataset, while 31 out
of the 50 GCI masses were significant (P < 0.05) in the
Osaka dataset. Likewise, the top 50 metabolites in the
Osaka study showed 88% and 94% redundancy with meta-
bolites showing P < 0.05 in the GCI and Seracare 1 stu-
dies, respectively. These results indicated a very high
degree of commonality among significantly differentiated
masses across the three studies, and in fact, 63% of the top
50 masses in each study were also present within the top
50 of at least one of the other two studies (see Additional
File 2). Of the top 50 rank-ordered masses, only those
identified in more than one study were found to exist
within the 440 to 600 Da mass range highlighted above
and there was not a single peak detected outside this
region which was significantly different between CRCs and
controls in any two of the studies. Filtering for metabolic
differences detected exclusively in all three studies (as well
as removal of C13 isotopic peaks and redundant masses
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representing individual
12C metabolites as shown in Table
3. These represented the most statistically significant and
robust discriminators among the three studies. Subsequent
molecular formula assignments, as discussed further
below, as well as related expression profiles, suggested that
the metabolites belonged to a related chemical family.
The relative intensities of the two lowest molecular
weight molecules with nominal masses of 446 and 448
are shown in Figure 3A. We observed little to no corre-
lation between the reduction of the metabolites and dis-
ease stage (Figures 3A and 3B), and ROC curve analysis
resulted in an average area under-the-curve (AUC) of
0.91 ± 0.03 (Figure 3C; individual AUCs shown) across
all three studies for all stages combined.
Computational assignments of reasonable molecular
formulas were then carried out for the 13 masses identi-
fied above, as well as the top 50 for each discovery set
shown in Additional File 2. The assignments were based
on a series of mathematical and chemometric rules as
described previously [23], which are reliant on high mass
accuracy for precise prediction. The algorithm computes
the number of carbons, hydrogens, oxygens and other
elements, based on their exact mass, which can be
assigned to a detected accurate mass within defined con-
straints. Logical putative molecular formulas were
Figure 1 Study design. The study comprised three phases: Fourier transform ion cyclotron resonance mass spectrometry metabolomic
discovery in three independent sample sets, structural investigation and determination of metabolic biomarkers as hydroxylated polyunsaturated
ultra long-chain fatty acids and validation using a triple-quadrupole multiple reaction monitoring targeted assay.
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resulting in elemental compositions containing either 28,
30, 32 or 36 carbons and four to six oxygen. We used
t h i si n f o r m a t i o ni nt h es u b s e q u e n ts e c t i o nt os e l e c t
appropriate molecules for structural comparison studies.
Collectively, the results indicated a consistent 50% to
75% reduction of organically soluble oxygenated metabo-
lites ranging between 28 and 36 carbons in length, in the
serum of CRC patients compared to controls.
Structural elucidation
Selected ethyl acetate extracts of serum from the GCI
cohort used in the FTICR-MS work described above
were re-analysed using HPLC coupled to a quadrupole
time-of-flight (Q-TOF) MS in full-scan APCI negative
ion mode. Consistent with the FTICR-MS results, a
cluster of peaks between approximately 440 and 600 Da
at a retention time of between 16 and 18 min following
reverse-phase HPLC was detected in asymptomatic con-
t r o ls e r a ,b u tw a sa b s e n tf r o mC R Cp a t i e n ts e r u m( F i g -
ure 4). Molecular ions from all six C28 biomarkers (m/z
446, m/z 448, m/z 450, m/z 464, m/z 466 and m/z 468)
as well as many of the remaining C32 and C36 markers
were easily detectable within normal serum. Extracted
masses up to 400 Da within the 16-18 min retention
time showed similar peak intensities in both populations
(Figure 4, region to the right of the box), as did
extracted mass spectra at other retention times (not
shown), reinforcing the specificity of this depleted meta-
bolic region for CRC patient serum.
Tandem mass spectrometric fragmentation finger-
prints were next generated for the six C28 biomarkers
(Table 4, see Additional Files 345678) and for the higher
C32 and C36 biomarkers (see Additional File 9). The
MS/MS and MS3 fragmentation data of the six C28 bio-
markers were dominated by peaks resulting from losses
of H2O (m/z 427, 429, 431, 445, 447 and 449), losses of
two molecules of H2O (m/z 409, 411, 413, 427, 429,
431), losses of CO2 (m/z 401, 403, 405, 419, 421, 423)
and losses of CO2 and H2O (m/z 383, 385, 387, 401,
403, 405), indicating the presence of carboxylic acid
functionality and two or more hydroxyl groups. The
molecular formulae, organic properties of the molecules
and the tandem MS data suggested that the metabolites
were derivatives or analogues of one or more possible
classes of molecules including fat soluble vitamins such
as retinol and retinoic acid (vitamin A), calciferols (vita-
min D), tocopherols (vitamin E), phylloquinones (vita-
min K), steroids or bile acids, or long chain
polyunsaturated hydroxy fatty acids. Tandem mass spec-
trometric fragmentation fingerprints of standards for
each of these metabolic classes were therefore generated
including 5S,6S-(7E,9E,11Z,14Z)-dihydroxyeicosatetrae-
noic acid (1), 15S-Hydroxy-(5Z,8Z,11Z,13E)-
Figure 2 Scatter plots of average sample peak intensity fold
change between colorectal cancer (CRC) and normal patient
sera in three independent studies. Sample-specific peaks for all
subjects were log2 normalized to the mean of the control
population, and plotted according to mass (Da). Points are coloured
according to significance based on an unpaired Students’t-test (see
legend). (A) Genomics Collaborative Inc discovery population, (B)
Seracare 1 discovery population, (C) Osaka discovery population. The
region boxed in grey represents the cluster of masses between 440
and 600 Da consistently reduced in the CRC patient population
compared to controls in all three cohorts.
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Page 7 of 20eicosatetraenoic acid (2)a n d8 R - H y d r o x y -
(5Z,9E,11Z,14Z)-eicosatetraenoic acid (3), a-tocopherol
(4) g-tocopherol (5), 13-(6-hydroxy-2,7,8-trimethylchro-
man-2-yl)-2,6,10-trimethyltridecanoic acid (6), 16-(4,5-
dimethyl-3,6-dioxo cyclohexa-1,4-dienyl)-2,6,10,14-tetra-
methylhexadecanoic acid (7), 6-hydroxy-2,7-dimethyl-2-
(4,8,12-trimethyltridecyl)chroman-8-carbaldehyde (8), 6-
hydroxy-2,7-dimethyl-2-(4,8,12-trimethyltridecyl)chro-
man-8-carboxylic acid (9), calciferol (10), cholecalciferol
(11), ergosterol (12), phylloquinone (13), retinol (14)
and 3b,7a-dihydroxy-5-cholestenoic acid (15)( T a b l e5 ) .
The resulting MS/MS data for vitamins A, D, E, K as
well as the steroidal molecules (4 - 15) showed no simi-
larity to any of the metabolomic biomarkers; for vitamin
E type molecules, all had diagnostic fragments charac-
teristic of their chroman rings (m/z 163, 149, 149, 149,
163 and 179 for 4, 5, 6, 7, 8 and 9 respectively), for
vitamin D and analogues, diagnostic fragments formed
as a result of the loss of the side chain (m/z 271, 273
and 253, for 10, 11 and 13, respectively), for phylloqui-
none (13), the diagnostic fragment m/z 187 for the qui-
none ring system was prominent, for vitamin A (14),
the fragment m/z 269 (M + H - H2O) loses the cyclo-
hexyl ring moiety to form a diagnostic m/z 145 for reti-
nol and for 3b,7a-dihydroxy-5-cholestenoic acid (15)
the diagnostic retro diels alder fragment at m/z 277 was
observed. In addition to this, other carboxylic acid stan-
dards with a pregnane ring system, as in 15 (for exam-
ple, chenodeoxycholic acid and cholic acid), do not
show losses of CO2 upon MS/MS fragmentation (not
shown). However, MS/MS fragmentation data of
hydroxy fatty acid standards 1, 2 and 3 (Table 5)
Table 2 Percent overlap between top 50 most discriminating masses (based on student’s t-test) of each discovery
project and masses showing P < 0.05 in the remaining cohorts
Genomics Collaborative (P < 0.05) Seracare (P < 0.05) Osaka (P < 0.05)
GCI (Top 50) - 46 (92%) 31 (62%)
Seracare 1 (Top 50) 35 (70%) - 27 (54%)
Osaka (Top 50) 44 (88%) 47 (94%) -
Figure 3 Relative intensities of metabolites 446 and 448 by disease stage and the area under the curves for each discovery dataset.
(A) Bar charts of relative intensity versus disease stage in each sample set; (B) summary of P-value comparisons between disease stages and
controls for metabolites 446 and 448; (C) receiver operating curve analysis based on markers 446 and 448 and all CRCs versus all controls in each
discovery set.
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Page 8 of 20showed peripheral cut ions similar to those produced by
MS/MS of the CRC biomarkers, and consistent with
what has been described by others for various hydroxy-
lated long-chain fatty acids [29-33]. For example, marker
m/z 446 showed peripheral cut ions 427 [M - H - H2O]
-
, 401 [M - H - CO2]
-, 409 [M - H - 2H2O]
-, 383 [M - H
-C O 2 -H 2O]
- a n d3 6 5[ M-H-C O 2 -2 H 2O]
- and
chain cut ions, 223, 205, 277 as well as others (see
Table 5 and Additional File 3). Similar ions were
obtained for the other C28, C32 and C36 metabolites
Table 3 List of 13 masses detected among the top 50 masses inclusive to all three discovery projects
GCI
Rank order Detected mass Molecular formula Part per million Analysis mode P value Ratio (CRC/normal)
6 446.3406 C28H46O4 2.22 NAPCI 6.4E-13 0.31
13 448.3563 C28H48O4 2.32 NAPCI 2.5E-12 0.41
8 466.3661 C28H50O5 0.59 NAPCI 9.4E-13 0.25
7 468.3840 C28H52O5 5.39 NAPCI 9.0E-13 0.27
21 492.3829 C30H52O5 2.89 NAPCI 8.5E-11 0.33
24 494.3977 C30H54O5 1.16 NAPCI 1.9E-10 0.35
29 518.3976 C32H54O5 0.92 NAPCI 1.6E-09 0.37
12 538.4259 C32H58O6 4.76 NAPCI 2.5E-12 0.30
44 574.4607 C36H62O5 1.7 NAPCI 1.6E-08 0.40
26 576.4771 C36H64O5 2.99 NAPCI 3.0E-10 0.37
32 578.4931 C36H66O5 3.59 NAPCI 3.2E-09 0.34
11 592.4711 C36H64O6 1.37 NAPCI 2.2E-12 0.27
15 594.4851 C36H66O6 1.41 NAPCI 6.3E-12 0.26
Seracare
45 446.3413 C28H46O4 3.79 NAPCI 1.8E-06 0.36
9 448.3570 C28H48O4 3.88 NAPCI 1.6E-08 0.36
3 466.3664 C28H50O5 1.23 NAPCI 8.5E-10 0.34
6 468.3847 C28H52O5 6.89 NAPCI 4.9E-09 0.36
17 492.3835 C30H52O5 4.11 NAPCI 4.6E-08 0.42
34 494.3971 C30H54O5 0.05 NAPCI 6.6E-07 0.41
11 518.3968 C32H54O5 0.63 NAPCI 2.2E-08 0.33
18 538.4263 C32H58O6 5.5 NAPCI 7.8E-08 0.38
32 574.4595 C36H62O5 0.39 NAPCI 6.1E-07 0.32
42 576.4768 C36H64O5 2.47 NAPCI 1.0E-06 0.37
49 578.4933 C36H66O5 3.93 NAPCI 3.2E-06 0.42
30 592.4721 C36H64O6 3.06 NAPCI 5.6E-07 0.27
50 594.4851 C36H66O6 1.41 NAPCI 3.7E-06 0.32
Osaka
6 446.3400 C28H46O4 0.87 NESI 1.8E-10 0.44
13 448.3556 C28H48O4 0.76 NESI 2.2E-09 0.54
1 466.3663 C28H50O5 1.02 NESI 2.9E-12 0.50
5 468.3815 C28H52O5 0.05 NESI 1.8E-10 0.49
4 492.3814 C30H52O5 0.15 NESI 7.1E-11 0.57
23 494.3969 C30H54O5 0.45 NESI 2.0E-07 0.62
39 518.3975 C32H54O5 0.72 NAPCI 5.8E-06 0.52
19 538.4237 C32H58O6 0.67 NESI 4.7E-08 0.58
16 574.4600 C36H62O5 0.48 NESI 3.8E-09 0.42
7 576.4756 C36H64O5 0.39 NESI 3.0E-10 0.42
14 578.4910 C36H66O5 0.04 NESI 2.6E-09 0.50
15 592.4703 C36H64O6 0.02 NESI 3.3E-09 0.41
3 594.4859 C36H66O6 0.07 NESI 6.8E-11 0.40
Indicated are the rank order based on P-value, detected accurate mass, the computationally predicted molecular formula, the mass difference between the
detected mass and mass of the predicted molecular formula in part per million, the mode of analysis (electrospray ionization, ESI; atmospheric pressure chemical
ionization, APCI), the P-value (based on an unpaired student’s t-test) between the average peak intensity of control subjects versus colorectal cancer (CRC)
patients, and the average peak intensity ratio between CRC patients and controls.
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Page 9 of 20(Table 4 and Additional File 9). Collectively, these
deductions indicated that the metabolomic markers
were not analogues of vitamins A, D, E, K and steroids,
but rather long-chain hydroxy fatty acids containing
varying degrees of unsaturation. We collectively refer to
these metabolites as hydroxylated polyunsaturated ultra
long-chain fatty acids (hPULCFAs; where the term
‘ultra’ has been used to refer to C30 and longer chain
fatty acids [34]).
Next, an enrichment strategy using bulk serum extracts
and a two-stage flash column chromatography
approach followed by nuclear magnetic resonance
(NMR) analysis was carried out to provide further
structural verification of th eh P U L C F A s .F i r s t ,r e v e r s e
phase FCC using a water-acetonitrile solvent gradient
was performed and the resulting fractions analysed by
LC/MS. Fractions containing the hPULCFAs (fraction
9, Additional Files 10 and 11) were pooled and sub-
jected to normal phase FCC using chloroform-metha-
nol mixtures to obtain an approximately 65% rich
semi-purified fraction labelled sample A (Additional
File 12). LC and MS/MS analyses (MS2 and MS3) data
Figure 4 Extracted mass spectrum of serum from normal subjects and colorectal cancer (CRC) patients. Extracts from five representative
CRC and five control samples from the Genomics Collaborative discovery set were subject to high performance liquid chromatography followed
by full-scan detection on an Applied Biosystems QSTAR XL™ mass spectrometer in atmospheric pressure chemical ionization negative mode. The
average intensities of all ions within the mass range 100 to 700 Da eluting between 16 and 18 min are shown for each cohort. The boxed
region indicates spectral features present in normal patients but absent from CRC-positive serum.
Ritchie et al. BMC Medicine 2010, 8:13
http://www.biomedcentral.com/1741-7015/8/13
Page 10 of 20on sample A were used to track and confirm enrich-
ment of the markers. NMR (
1H,
13C and 2D) analyses
on sample A and its methyl esters revealed resonances
and correlations (Table 6) consistent with very long
chain polyunsaturated hydroxy fatty acids with obser-
vance of some suppression of resonances for hydrogen
atoms attached to sp
2 carbons.
Independent validation using MRM methodology
Reduced levels of hPULCFAs in the blood of CRC patients
was further confirmed using a MS/MS approach (see
methods) in two more independent populations. The
approach is based upon the measurement of parent-
daughter fragment ion combinations (referred to as
MRM) for quantifying analytes [28,35]. We developed an
assay to specifically measure semi-quantitatively three of
the 28 carbon hPULCFAs with four oxygens (parent
masses 446, 448 and 450; C28H46O4, C28H48O4 and
C28H50O4, respectively) as described in the methods. The
first study comprised 70 treatment-naive CRC subjects
and 70 matched controls, all of which were Caucasians
from the USA. The [
13C1]cholic acid equivalent concentra-
tions of the three 28-carbon hPULCFAs (named according
to nominal mass 446, 448 and 450) for each subject are
shown in Figure 5A. Significantly lower levels (P < 0.001,
actual values shown in Figure 5A) of each of the metabo-
lites was observed in treatment-naive CRC-positive sub-
jects compared to controls. ROC analysis resulted in
AUCs of 0.87 ± 0.005 for each of the 28-carbon containing
hPULCFAs (Figure 5B). Plotting patients by disease stage
showed a slight (but not significant) reduction between
stage I and III, with stage IV subjects showing the least
reduction (Figures 5C and 5D), albeit it only seven sub-
jects. The corresponding average AUCs of the 28-carbon
pool by stage were 0.87 for stage I, 0.88 for stage II, 0.94
for stage III and 0.66 for stage IV.
We next used the MRM method to characterize another
independent population of CRC and control subjects from
Chiba, Japan. Serum from 40 pre-treatment CRC subjects
and 40 controls were analysed and a significant reduction
was again observed in the CRC-positive group (Figure
6A). The corresponding average AUC for the three meta-
bolites was 0.97 ± 0.014 (Figure 6B). In this study, a signifi-
cant correlation with stage was observed (P < 0.05) for all
comparisons between stages I, II and III/IV (Figures 6C
and 6D). The AUCs by stage were 0.93 for stage I, 0.97 for
stage II and 1.0 for stage III/IV (two stage IVs were
grouped with stage III; Figure 6D).
Discussion
We report here on the discovery of novel hydroxylated
polyunsaturated ultra long-chain fatty acids containing
between 28 and 36 carbons reduced in the serum of CRC
patients compared to healthy asymptomatic controls. The
utility of non-targeted metabolomics using high resolution
FTICR-MS coupled with flow injection technology for bio-
marker discovery was demonstrated by applying the tech-
nology to three independent test populations. In contrast
to the ‘training/test-set’ approach often used by splitting a
single sample set in half to validate the performance of
biomarkers [36-38], which often relies on complex algo-
rithms (see review [39]) and can result in bias [40], we car-
ried out fully independent discovery analyses on three
separate sample sets of matched cases and controls of dif-
ferent ethnic backgrounds collected from multiple sites
a r o u n dt h ew o r l dt oe n s u r eah i g hd e g r e eo fr o b u s t n e s s
and minimal chance of sampling bias. Of the top 50 meta-
bolic discriminators discovered in the Osaka set, 44 and
47 of these were also significantly changed in the GCI and
Seracare sets, respectively. This remarkable inter-study
agreement indicates that not only is non-targeted FTICR-
MS technology a reproducible biomarker discovery engine,
but that disease-related metabolomic changes can be
highly conserved across geographic locations and races.
The reduction of hPULCFAs in the serum of CRC patients
was further validated by translation of the non-targeted
FTICR-MS discovery into a simple targeted TQ-MRM
method for three hPULCFAs, which was used on two
further independent and ethnically diverse case-control
test populations. ROC AUCs generated from the TQ-
MRM method on the two validation studies were consis-
tent with those based upon the same fatty acids detected
in the three FTICR-MS discovery studies (Figures 3, 5 and
6). In total, five independent study populations collectively
comprising 222 treatment-naive CRC patient samples and
220 disease-free asymptomatic controls were evaluated
using two different analytical methods. Indeed, the likeli-
hood of the reported association between the reduction of
hPULCFAs and CRC being a false positive result across
the five independent sets of samples is astronomically low.
Meta-analysis was performed on the false positive rates
using Fisher’s Inverse Chi-square Method
( Reject H if P p C i i
k
     0 1 2  
  log ; p = P-values of five inde-
pendent samples, k = five different samples, C = upper tail
of the chi-square distribution with 2 k degrees of freedom
( X00 51 0
2
., = 18.31))[41,42]. Based upon the meta-analysis,
the resulting P-values for markers 446 and 448 were more
significant than the individual P-values, at 2.96 × 10
-47 and
8.11 × 10
-49, respectively. Although there were differences
in the median ages between the CRC and control cohorts
in two of the studies, there was no statistically significant
trend between age and hPULCFA levels within the indivi-
dual cohorts and we observed no significant difference
between hPULCFA concentrations among the controls
from the different populations (not shown). We also
observed no differences between genders, and although
there were slightly higher BMI levels in the control
c o h o r t sf o rt h eG C Ia n dS e r a c a r e1c o h o r t s ,t h eB M I s
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tion suggesting the markers are not related to BMI. A pro-
spective analysis of disease-free subjects equally
distributed across various age groups is underway specifi-
cally to address any potential age or BMI effects in more
detail. Overall our results indicate with a high degree of
confidence that a reduction in these metabolites is corre-
lated with the presence of CRC.
The FTICR-MS provided resolution sufficient for con-
fident molecular formula predictions based upon accu-
rate mass in conjunction with extraction, ionization, and
statistical correlative information. Although multiple ele-
mental compositions were theoretically assignable to
given biomarker masses, only formulas having 28 to 32
carbons, and four to six oxygen were consistently
assignable to common masses detected in two or three
of the discovery sets. Given a high degree of statistical
interaction between the sample-to-sample expression
profiles of the hPULCFAs (that is, a high degree of
correlation between the relative intensities of the mar-
kers across subjects) we suspected they were all part of
the same metabolic system and should therefore show
related compositions. Detection in negative ionization
mode also reduced the likelihood that nitrogen was pre-
sent in any of the compositions. This information in
conjunction with tandem mass spectrometry showing
prominent losses of water and carbon dioxide enabled
the determination of molecular formulas as shown in
Table 3 and Additional File 2. A number of candidate
classes of molecules theoretically fitting the molecular
formula class were easily excluded using tandem MS.
For example, we observed no fragments indicative of
condensed ring systems such as those in steroids or
vitamin D, and no fragments indicative of chroman ring
systems such as those observed in the vitamin E toco-
pherols. Several other classes of molecules including
vitamin K and retinol, and bile acids such as cholic acid
and 3b,7a-dihydroxy-5-cholestenoic acid also did not
Table 4 Tandem-mass spectrometry (MS) analysis of selected 28-carbon containing masses
Marker nominal neutral mass 446 448 450 464 466 468
[M-H]-(%) 445 (100%) 447 (52%) 449 (92%) 463 (70%) 465 (100%) 467 (100%)
Chain cut ions (%) 223 (18%) 277 (11%) 171 (7%) 277 (10%) 241 (7%) 187 (12%)
222 (11%) 239 (5%) 127 (9%) 241 (68%) 223 (3%) 169 (3%)
207 (3%) 207 (3%) 125 (12%) 223 (15%) 215 (2%) 141 (2%)
205 (11%) 169 (6%) 113 (38%) 185 (8%) 185 (4%) 113 (4%)
113 (5%) 113 (25%) 167 (4%) 167 (4%)
113 (28%) 113 (7%)
Peripheral cut ions (%) Loss of H2O 427 (50%) 429 (35%) 431 (80%) 445 (46%) 447 (45%) 449 (84%)
Loss of 2H2O 409 (8%) 411 (6%) 413 (13%) 427 (6%) 429 (8%) 431 (10%)
Loss of CO2 401 (95%) 403 (100%) 405 (100%) 419 (100%) 421 (45%) 423 (25%)
Loss of CO2and H2O 383 (28%) 385 (15%) 387 (32%) 401 (24%) 403 (20%) 405 (13%)
*Loss of CO2and 2H2O 365 367 369 383 (2%) 385 (4%) 387 (3%)
*Loss of 3H2O 409 411 413
Secondary daughter ions (%) 357 (5%) 331 (3%) 307 (5%) 347 (5%) 349 (4%) 349 (1%)
329 (11%) 305 (3%) 291 (7%) 319 (5%) 321 (2%) 323 (2%)
261 (3%) 359 (2%) 295 (5%) 295 (6%) 297 (3%) 309 (2%)
241 (3%) 289 (3%) 281 (5%) 281 (5%) 281 (3%) 297 (6%)
233 (5%) 245 (3%) 279 (9%) 279 (5%) 279 (15%) 281 (3%)
207 (11%) 125 (6%) 263 (7%) 267 (5%) 261 (3%) 279 (5%)
177 (11%) 123 (3%) 261 (5%) 249 (6%) 251 (3%) 269 (5%)
123 (5%) 121 (3%) 169 (5%) 195 (10%) 195 (2%) 263 (8%)
109 (11%) 111 (5%) 111 (5%) 141 (1%) 141 (2%) 251 (4%)
97 (16%) 97 (5%) 97 (8%) 127 (9%) 123 (4%) 243 (2%)
83 (11%) 59 (3%) 83 (5%) 121 (6%) 113 (5%) 215 (4%)
59 (11%) 59 (1%) 101 (6%) 101 (3%) 213 (3%)
97 (4%) 97 (32%) 197 (3%)
83 (2%) 83 (2%) 125 (4%)
59 (2%) 59 (2%) 111 (3%)
98 (2%)
57 (1%)
*Ions m ay have been obtained from MS
3 experiments
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Page 13 of 20show comparable fragmentation patterns. However, the
similarity in fragmentation pattern, particularly in the
relative abundances of daughter ions resulting from
losses of CO2 and H2O, and chain cut ions from the
hPULCFAs to known hydroxy fatty acid standards as
well as other fatty acids reported in the literature such
as the resolvins and protectins (discussed below),
allowed for the identification of the metabolites as
hydroxylated polyunsaturated ultra long-chain fatty
acids. Examination of the MS/MS data for the C28 ser-
ies (masses 446, 448, 450, 464, 466 and 448) revealed a
consistent 113 Da daughter ion, which we conjecture to
represent the carboxy-terminus chain fragment -CH2-
CH=CH-CH2-CH2-COOH. In addition, a consistent loss
of 54 (-CH=CH-CH2-CH2-) from the [M-(CO2+H2O)]
daughter ion was observed for the 446, 448, 464 and
466, but not the 450 and 468 molecules, suggesting that
(1) the 450 and 468 may have a saturated carboxy term-
inal region and (2), that there are likely no hydroxyl
moieties within this region of the molecule. MS/MS
data of all the C28 and other markers also did not show
the diagnostic fragment obtained with a 1,2-diol motif
as observed for 1 (base peak is chain cut ion at m/z
115) and NMR on fractions enriched via flash-column
chromatography showed lower than expected integration
values obtained for the
1HN M Rs i g n a l sa tδ 2.78
(methylene interruptions between double bond carbons)
and at δ 5.12 - 5.90 (hydrogen atoms on double bond
carbons). Cumulatively these results suggested that the
hydroxyl groups in the molecules are likely bonded to
the carbon atoms between the sp
2 carbons at least seven
carbons from the carboxy end. Confirmation of the
exact positions of the hydroxyl groups and precise loca-
tions of unsaturations in individual hPULCFAs using
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Table 6
1H nuclear magnetic resonance (NMR) data of
colorectal cancer (CRC) biomarker pool (sample A) and
their methyl esters
Types of
protons
CRC biomarker
pool
Methyl esters of CRC
biomarker pool
CH3 0.83-0.90 0.83-0.90
CH2 1.21-1.24, m 1.21-1.24, m
-CH2CH2COOH 1.57-1.65, m 1.53-1.69, m
-CH2CH=CH- 1.98-2.08, m 1.94-2.03, m
CH2COO 2.23-2.28, m 2.23-2.31, m
-CH=CH-CH2-
CH=
2.75-2.79, m 2.74-2.82, m
OCH3 - 3.64, s
-CH(OH)CH= 3.45-3.71, 4.03-4.26 4.02-4.12, 4.16-4.26, 4.58-4.60
-CH= 5.10-5.47, m 5.08-5.40, m
-CH(OH)CH= 5.76-5.91, m 5.75-5.90, m
*NMR solvent is CDCl3, signals assigned using 2D NMR experiments (HMQC
and HMBC)
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Page 14 of 20preparatory HPLC and chemical synthesis is in progress
and will be reported in subsequent publications.
Interestingly, the metabolite markers reported in this
study represent a human-specific metabolic system. We
analysed serum samples from multiple species, including
rat, mouse and bovine, as well as multiple different sam-
ple sources including numerous cell lines, conditioned
media, tumour and normal colonic tissue from patients
in the GCI discovery set, and brain, liver, adipose and
other tissues from various species, all of which failed to
show any detectable levels of these hPULCFAs (results
not shown). We also could not detect these molecules
in various plant tissues or grains, including policosanol
extracts which are rich in saturated C28 and longer-
c h a i nf a t t ya c i d s[ 4 3 , 4 4 ] .T h i ss u g g e s t st h a tt h em o l e -
cules may originate from human-specific metabolic
Figure 5 Results of triple-quadrupole multiple reaction monitoring analysis of the Seracare 2 validation sample set. (A) Scatter plots of
the concentrations of hydroxylated polyunsaturated ultra long chain fatty acids (hPULCFAs) 446, 448 and 450 expressed as [
13C1]-cholic acid
equivalents in asymptomatic normal controls and pre-treatment colorectal cancer patients, (B) receiver operating curve (ROC) analysis based
upon the corresponding scatter plots in (A). Grey dotted lines indicate the 95% confidence interval. (C) Bar charts of the average concentration
equivalents of hPULCFAs by disease stage. Error bars represent standard errors of the mean. (D) ROC analysis by disease stage.
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Page 15 of 20processes, such as specific p450-mediated and/or micro-
biotic processes. The lack of detection in tumour or
normal colonic tissue suggests that the metabolites are
not ‘tumour-derived markers’ and, combined with the
high rate of association in stage I cancer, it is not likely
that the reduction is the result of tumour burden. Ana-
lysis of post-surgery samples is currently in progress to
address this question. However, the further reduction of
levels observed in some late stage Japanese cases (Figure
6) could be explained if lower levels of the hPULCFAs
were indeed indicative of progression rate in this group.
It is also important to note that in all control groups
reported in this paper, subjects were not colonoscopy-
confirmed to be free of tumours or advanced neoplasia.
Based upon colonoscopy results by Collins et al in aver-
age-risk subjects, up to 10% of an asymptomatic popula-
tion can be positive for advanced neoplasia [45].
Therefore, the ability of these metabolites to discrimi-
nate between subjects at risk and not at risk for CRC is
likely under-estimated in our results. Studies are
Figure 6 Results of triple-quadrupole multiple reaction monitoring analysis of the Chiba validation sample set. (A) Scatter plots of the
concentrations of hydroxylated polyunsaturated ultra long-chain fatty acids (hPULCFAs) 446, 448 and 450 expressed as [
13C1]-cholic acid
equivalents in asymptomatic normal controls, and pre-treatment colorectal cancer patients, (B) receiver operating curve (ROC) analysis based
upon the corresponding scatter plots in (A). Grey dotted lines indicate the 95% confidence interval. (C) Bar charts of the average concentration
equivalents of hPULCFAs by disease stage. Error bars represent standard errors of the mean. (D) ROC analysis by disease stage.
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Page 16 of 20currently in progress to evaluate endoscopy-confirmed
controls, to assess the effect of treatment on the mar-
kers, and to investigate any possible association with
various grades of colon pathologies and non-malignant
GI disorders as well as other cancers.
Although fatty acids of this length containing hydroxyl
groups have never been reported as far as we are aware,
they appear to resemble a class of hydroxylated very
long-chain fatty acids knows as the resolvins and protec-
tins that originate from the n3 essential fatty acids EPA
and DHA, respectively, which are critical in promoting
the resolution of acute inflammation. The inability to
sufficiently ‘resolve’ acute inflammation is the leading
theory behind the establishment of chronic inflamma-
tory states which underlie multiple conditions including
cancer [46] and Alzheimer’s Disease [47]. Of particular
relevance is the effect of pro-resolution long-chain
hydroxy fatty acid mediators on intestinal inflammatory
conditions such as irritable bowl disease (IBD), Crohn’s
Disease, Colitis and colon cancer. Both Resolvin E1
(RvE1) and Lipoxin A4 (LXA4) have been implicated
with protective effects against colonic inflammation.
RvE1 was shown to protect against the development of
2,4,6-trinitrobenze sulphonic acid-induced colitis in
mice, accompanied by a block in leukocyte infiltration,
decreased proinflammatory gene expression, induced
nitric oxide synthase, with improvements in survival
rates and sustained body weight [48]. Similarly, LXA4
analogues have been shown to attenuate chemokine
secretion in human colon ex vivo [49], and attenuated
50% of genes, particularly those regulated by NFB
induced in response to pathogenically induced gastroen-
teritis [50]. In vivo, LXA4 analogues reduced intestinal
inflammation in DSS-induced inflammatory colitis,
resulting in significantly reduced weight loss, haemato-
chezia and mortality [50]. Structurally, resolvins and
protectins (as well the n6 lipoxins) comprise mono-, di-
and tri-hydroxylated products of the parent VLCFAs,
catalyzed by various lipoxygenases, cyclooxygenases and
p450 enzymes [51-55]. The possibility that the hPULC-
FAs reported here represent elongation products of
these molecules cannot be excluded. Future studies will
be required to address the origin, as well as the biologi-
cal role, if any, that these molecules may play in defend-
ing the body against CRC development.
Although we report results from multiple case-control
cohorts each having a limited sample size, the average
AUC across all the samples reported here was 0.91 ±
0.04, which translates into approximately 75% sensitivity
at 90% specificity with little to no disease-stage bias.
The real-world screening performance is currently being
evaluated through two large ethically approved prospec-
tive clinical trials, one in collaboration with the Sas-
katchewan Cancer Agency and the Saskatchewan
Provincial Government (PDI-CT-1; n = 5000), and the
other with the University of Calgary (PDI-CT-3 n =
1500). Clinically relevant questions are being addressed,
including correlation between hPULCFAs and CRC in a
prospective hospital screening environment, correlation
with other non-malignant gastrointestinal disorders
(such as IBD, Crohn’s and colitis), whether there is any
correlation with various stages of neoplasia or polyps
and family history and whether subjects with low
hPULCFA levels show higheri n c i d e n c er a t e so fC R C
than subjects with ‘normal’ levels over time.
In summary, we have identified a consistent reduction of
novel circulating hPULCFAs in CRC patients which could
have considerable implications for CRC diagnosis and
screening and possibly prevention and treatment. Adher-
ence to currently recommended screening modalities,
namely faecal occult blood testing and colonoscopy, is
poor due to a number of factors including public accep-
tance, risk, cost and available resources. The use of a
serum-based test to screen the population for subjects who
are high risk would focus endoscopy resources on subjects
who need it the most, resulting in a higher detection rate,
particularly in early stages of the disease. Given the positive
prognosis of early-stage therapeutic intervention, it is
tempting to speculate that hPULCFA-based screening
could one day result in decreased CRC mortality.
Conclusions
We have shown that comprehensive non-targeted metabo-
lomics technology based upon high-resolution FTICR mass
spectrometry represents a powerful and robust approach
for small-molecule biomarker-driven discovery. Accurate
mass measurements combined with conventional MS/MS
resulted in the rapid identification of key structural charac-
teristics of the novel metabolites discovered and the assign-
ment of putative chemical structures. The subsequent
translation of these metabolite biomarker discoveries into
an efficient and clinically viable high-throughput semi-
quantitative triple-quadrupole platform represents a signifi-
cant advancement in the clinical implementation of bio-
marker discoveries. The reduction of systemic
hydroxylated ultra-long chain fatty acids in CRC patients
raises intriguing biological and aetiological questions given
the large numbers of sporadic CRC cases and the heavy
influence of lifestyle and diet on risk. Further research is
ongoing regarding the potential role(s) these novel mole-
cules play in CRC progression and whether they have any
association with previously established risk factors.
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Additional file 10: Purification process to obtain hydroxylated
polyunsaturated ultra long-chain fatty acids (hPULCFA) enriched
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